瑞舒伐他汀对高血压病并血脂异常患者高敏C-反应蛋白及胰岛素抵抗的影响

关健, 李水轩. 瑞舒伐他汀对高血压病并血脂异常患者高敏C-反应蛋白及胰岛素抵抗的影响[J]. 临床心血管病杂志, 2014, 30(2): 150-152. doi: 10.13201/j.issn.1001-1439.2014.02.019
引用本文: 关健, 李水轩. 瑞舒伐他汀对高血压病并血脂异常患者高敏C-反应蛋白及胰岛素抵抗的影响[J]. 临床心血管病杂志, 2014, 30(2): 150-152. doi: 10.13201/j.issn.1001-1439.2014.02.019
GUAN Jian, LI Shuixuan. Effects of rosuvastatin on high-sensitivity C-reactive protein and insulin resistance in patients with hypertension and hyperlipidemia[J]. J Clin Cardiol, 2014, 30(2): 150-152. doi: 10.13201/j.issn.1001-1439.2014.02.019
Citation: GUAN Jian, LI Shuixuan. Effects of rosuvastatin on high-sensitivity C-reactive protein and insulin resistance in patients with hypertension and hyperlipidemia[J]. J Clin Cardiol, 2014, 30(2): 150-152. doi: 10.13201/j.issn.1001-1439.2014.02.019

瑞舒伐他汀对高血压病并血脂异常患者高敏C-反应蛋白及胰岛素抵抗的影响

详细信息
  • 中图分类号: R544.1

Effects of rosuvastatin on high-sensitivity C-reactive protein and insulin resistance in patients with hypertension and hyperlipidemia

  • 目的:探讨瑞舒伐他汀对高血压病并血脂异常患者高敏C-反应蛋白 (hs-CRP) 及胰岛素抵抗 (IR) 的影响。方法:选取高血压病并血脂异常患者100例, 随机分为试验组及对照组, 每组50例, 均予降压治疗, 试验组加用瑞舒伐他汀10mg/d, 治疗时间为8周。另选取年龄、性别等相匹配的50例正常体检者作为健康组。观察治疗前后血压、血脂、血糖、hs-CRP、胰岛素抵抗指数 (HOMA-IR) 等指标变化。结果:试验组及对照组治疗前血清hs-CRP、HOMA-IR、血压、总胆固醇 (TC)、三酰甘油 (TG)、低密度脂蛋白胆固醇 (LDL-C) 水平均高于健康组 (均P<0.05), 而高密度脂蛋白胆固醇 (HDL-C) 低于健康组 (P<0.05);相关分析示hs-CRP与HOMA-IR呈正相关 (r=0.527, P<0.05)。试验组治疗8周后, 与治疗前相比血压、血清hs-CRP、HOMA-IR、血压、TC、TG、LDL-C水平均明显下降 (均P<0.05), HDL-C水平升高 (P<0.05), BMI差异无统计学意义;对照组与治疗前相比, 血压明显下降 (P<0.01), 余指标治疗前后差异无统计学意义;两组治疗后TC、LDL-C、HDL-C、HOMA-IR及hs-CRP水平比较差异有统计学意义 (均P<0.05)。结论:瑞舒伐他汀治疗高血压病并血脂异常患者, 调脂同时降低HOMA-IR及血清hs-CRP水平, 有抗炎及改善IR的作用。
  • 加载中
  • [1]

    李霞, 周智广, 亓海英, 等.用空腹C肽代替胰岛素改良HOMA公式评价IR和胰岛β细胞功能[J].中南大学学报 (医学版), 2004, 29 (4):419-423.

    [2]

    CAM H, PÜŞÜROGLU K, AYDIN A, et al.Effects of hemorheological factors on the development of hypertension in diabetic children[J].J Trop Pediatr, 2003, 49:164-167.

    [3]

    FASSHAUER M, KRALISCH S, KLIER M, et al.Adiponectin gene expression and secretion is inhibited by interleukin-6in 3T3-L1adipocytes[J].Biochem Biophys Res Commun, 2003, 301:1045-050.

    [4]

    FESTA A, D'AGOSTINO R, HOWARD G, et al.Chronic subclinical inflammation as part of the insulin resistance syndrome:the Insulin Resistance Atherosclerosis Study (IRAS)[J].Circulation, 2000, 102:42-47.

    [5]

    BAKER W L, TALATI R, WHITE C M, et al.Differing effect of statins on insulin ensitivity in non-diabetics:a systematic review and meta-analysis[J].Diabetes Res Clin Pract, 2010, 87:98-107.

    [6]

    WEYER C, YUDKIN J S, STEHOUWER C D, et al.Humoral markers of inflammation and endothelial dysfunetion in relation to adiposity and in vivo insulin action in Pima Indians[J].Atheroselerosis, 2002, 161:233-242.

  • 加载中
计量
  • 文章访问数:  44
  • PDF下载数:  17
  • 施引文献:  0
出版历程
收稿日期:  2013-04-09
修回日期:  2013-06-18

目录